PCSK9 and type 1 diabetes mellitus: Additionally, studies investigating PCSK9 inhibitors specifically in T1D populations, integrating CGM metrics with CV risk assessment, and addressing guidelines and limitations to optimal statin use in eligible patients with T1D are essential to improve evidence-based care and cardiovascular outcomes in this high-risk population.